Gritstone bio, Inc. 2JQ.F Stock
Gritstone bio, Inc. Price Chart
Gritstone bio, Inc. 2JQ.F Financial and Trading Overview
| Gritstone bio, Inc. stock price | 0.68 EUR |
| Previous Close | 2.05 EUR |
| Open | 2.03 EUR |
| Bid | 2.03 EUR x 0 |
| Ask | 2.11 EUR x 0 |
| Day's Range | 2.03 - 2.03 EUR |
| 52 Week Range | 1.52 - 5.29 EUR |
| Volume | 200 EUR |
| Avg. Volume | 178 EUR |
| Market Cap | 180.05M EUR |
| Beta (5Y Monthly) | 0.53841 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.19 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 32.18 EUR |
2JQ.F Valuation Measures
| Enterprise Value | 84.8M EUR |
| Trailing P/E | N/A |
| Forward P/E | -0.9375 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 11.847736 |
| Price/Book (mrq) | 1.2624689 |
| Enterprise Value/Revenue | 5.58 |
| Enterprise Value/EBITDA | -0.71 |
Trading Information
Gritstone bio, Inc. Stock Price History
| Beta (5Y Monthly) | 0.53841 |
| 52-Week Change | 7.08% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.29 EUR |
| 52 Week Low | 1.52 EUR |
| 50-Day Moving Average | 2.15 EUR |
| 200-Day Moving Average | 2.63 EUR |
2JQ.F Share Statistics
| Avg. Volume (3 month) | 178 EUR |
| Avg. Daily Volume (10-Days) | 1K EUR |
| Shares Outstanding | 88.91M |
| Float | 66.83M |
| Short Ratio | N/A |
| % Held by Insiders | 2.42% |
| % Held by Institutions | 53.37% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -830.95% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -34.81% |
| Return on Equity (ttm) | -75.59% |
Income Statement
| Revenue (ttm) | 15.2M EUR |
| Revenue Per Share (ttm) | 0.16 EUR |
| Quarterly Revenue Growth (yoy) | -66.00000000000000000000000000000000% |
| Gross Profit (ttm) | -91458000 EUR |
| EBITDA | -119511000 EUR |
| Net Income Avi to Common (ttm) | -124753000 EUR |
| Diluted EPS (ttm) | -1.19 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 145.81M EUR |
| Total Cash Per Share (mrq) | 1.64 EUR |
| Total Debt (mrq) | 48.78M EUR |
| Total Debt/Equity (mrq) | 34.63 EUR |
| Current Ratio (mrq) | 6.273 |
| Book Value Per Share (mrq) | 1.604 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -122585000 EUR |
| Levered Free Cash Flow (ttm) | -61789000 EUR |
Profile of Gritstone bio, Inc.
| Country | Germany |
| State | CA |
| City | EmeryVille |
| Address | 5959 Horton Street |
| ZIP | 94608 |
| Phone | 510 871 6100 |
| Website | https://gritstonebio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 233 |
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Q&A For Gritstone bio, Inc. Stock
What is a current 2JQ.F stock price?
Gritstone bio, Inc. 2JQ.F stock price today per share is 0.68 EUR.
How to purchase Gritstone bio, Inc. stock?
You can buy 2JQ.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Gritstone bio, Inc.?
The stock symbol or ticker of Gritstone bio, Inc. is 2JQ.F.
Which industry does the Gritstone bio, Inc. company belong to?
The Gritstone bio, Inc. industry is Biotechnology.
How many shares does Gritstone bio, Inc. have in circulation?
The max supply of Gritstone bio, Inc. shares is 108.57M.
What is Gritstone bio, Inc. Price to Earnings Ratio (PE Ratio)?
Gritstone bio, Inc. PE Ratio is now.
What was Gritstone bio, Inc. earnings per share over the trailing 12 months (TTM)?
Gritstone bio, Inc. EPS is -1.19 EUR over the trailing 12 months.
Which sector does the Gritstone bio, Inc. company belong to?
The Gritstone bio, Inc. sector is Healthcare.